ArticleFrontiers in cellular and infection microbiology2026
Whole-genome sequencing reveals molecular characterization of carbapenem-resistant
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To characterize the molecular characteristics of carbapenem-resistant Methods: A total of 106 non-duplicate clinical isolates of CRPA were collected from January 2019 to December 2023 at Science City Hospital in Sichuan Province, China. Antimicrobial susceptibility testing was performed to characterize the resistance profiles of the isolates. Whole-genome sequencing (WGS) was conducted to comprehensively characterize the sequence types (STs), virulence factors, and resistance genes. Pulsed-field gel electrophoresis (PFGE) was employed to analyze DNA fingerprinting patterns, clarifying the clonal relatedness among strains and tracing potential clonal dissemination. Results: Antimicrobial susceptibility testing demonstrated that all 106 CRPA isolates were resistant to imipenem. Consistent resistance to cefazolin and cefotetan were observed in 103 isolates. ST640 was identified as the predominant type, along with two novel STs, designated ST4440 and ST4513. Molecular characterization revealed that all isolates carried the efflux pump genes (mexA, mexB), the blaPDC (AmpC enzyme) gene and blaOXA-50, while metallo-β-lactamase genes were detected in only two isolates. All 106 isolates carried virulence gene exoT, with exoY and exoS detected in 98.1% and 91.5%, respectively. PFGE results showed that no predominant clone was observed at the 85% similarity level, suggesting that the isolates were mainly from sporadic infections. Conclusion: Resistance in CRPA isolates is predominantly mediated by efflux pumps and AmpC enzymes, along with the presence of the blaOXA-50. The observed high genetic diversity underscores the need for enhanced infection control measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.